Lurasidone exerts antidepressant properties in the chronic mild stress model through the regulation of synaptic and neuroplastic mechanisms in the rat prefrontal cortex

International Journal of Neuropsychopharmacology

Volumn 18, Issue 4, 2015, Pages 1-12

  Luoni, Alessia ^a   Macchi, Flavia ^a   Papp, Mariusz ^b   Molteni, Raffaella ^a   Riva, Marco A ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

BDNF; Chronic mild stress; Glutamate; Lurasidone; Synaptic mechanisms

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; LURASIDONE; MESSENGER RNA; NEUROTROPHIN; POSTSYNAPTIC DENSITY PROTEIN 95; SUCROSE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EEF2; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; DLGH4 PROTEIN, RAT; EEF2K PROTEIN, RAT; ELONGATION FACTOR 2 KINASE; EXCITATORY AMINO ACID TRANSPORTER 2; EXCITATORY AMINO ACID TRANSPORTER 3; MEMBRANE PROTEIN; MTOR PROTEIN, RAT; SIGNAL PEPTIDE; SLC17A7 PROTEIN, RAT; SLC1A1 PROTEIN, RAT; SLC1A2 PROTEIN, RAT; TARGET OF RAPAMYCIN KINASE; VESICULAR GLUTAMATE TRANSPORTER 1;

3' UNTRANSLATED REGION; ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR DISORDER; CELL LEVEL; CHRONIC STRESS; CONTROLLED STUDY; DEPRESSION; DOWN REGULATION; FUNCTIONAL STATUS; MAJOR DEPRESSION; MALE; NEUROMODULATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYNAPSE; SYNAPTIC TRANSMISSION; ANIMAL; CHRONIC DISEASE; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; MENTAL STRESS; METABOLISM; RANDOMIZATION; WISTAR RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHRONIC DISEASE; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; ELONGATION FACTOR 2 KINASE; EXCITATORY AMINO ACID TRANSPORTER 2; EXCITATORY AMINO ACID TRANSPORTER 3; GENE EXPRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LURASIDONE HYDROCHLORIDE; MALE; MEMBRANE PROTEINS; PREFRONTAL CORTEX; RANDOM ALLOCATION; RATS, WISTAR; RNA, MESSENGER; STRESS, PSYCHOLOGICAL; TOR SERINE-THREONINE KINASES; VESICULAR GLUTAMATE TRANSPORT PROTEIN 1;

EID: 84939194287     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyu061     Document Type: Article

References (56)

1. An JJ, Gharami K, Liao GY, Woo NH, Lau AG, Vanevski F, Torre ER, Jones KR, Feng Y, Lu B, Xu B (2008) Distinct role of long 3' UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons. Cell 134:175-187.
2. Araya-Callis C, Hiemke C, Abumaria N, Flugge G (2012) Chronic psychosocial stress and citalopram modulate the expression of the glial proteins GFAP and NDRG2 in the hippocampus. Psychopharmacology 224:209-222.
3. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-95.
4. Autry AE, Monteggia LM (2012) Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 64:238-258.
5. Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G (2010) Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 15:501-511.
6. Banasr M, Dwyer JM, Duman RS (2011) Cell atrophy and loss in depression: reversal by antidepressant treatment. Curr Opin Cell Biol 23:730-737.
7. Calabrese F, Molteni R, Cattaneo A, Macchi F, Racagni G, Gennarelli M, Ellenbroek BA, Riva MA (2010) Long-term duloxetine treatment normalizes altered brain-derived neurotrophic factor expression in serotonin transporter knockout rats through the modulation of specific neurotrophin isoforms. Mol Pharmacol 77:846-853.
8. Calabrese F, Molteni R, Riva MA (2011) Antistress properties of antidepressant drugs and their clinical implications. Pharmacol Ther 132:39-56.
9. Cates LN, Roberts AJ, Huitron-Resendiz S, Hedlund PB (2013) Effects of lurasidone in behavioral models of depression. Role of the 5-HT? receptor subtype. Neuropharmacology 70:211-217.
10. Chourbaji S, Brandwein C, Vogt MA, Dormann C, Hellweg R, Gass P (2008) Nature vs. nurture: can enrichment rescue the behavioral phenotype of BDNF heterozygous mice? Behav Brain Res 192:254-258.
11. Chourbaji S, Hörtnagl H, Molteni R, Riva MA, Gass P, Hellweg R (2012) The impact of environmental enrichment on sexspecific neurochemical circuitries: effects on brain-derived neurotrophic factor and the serotonergic system. Neurosci 220:267-276.
12. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46-56.
13. de Kloet ER, Joels M, Holsboer F (2005) Stress and the brain: from adaptation to disease. Nat Rev Neurosci 6:463-475.
14. Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science 338:68-72.
15. Elizalde N, Pastor PM, Garcia-Garcia AL, Serres F, Venzala E, Huarte J, Ramirez MJ, Del Rio J, Sharp T, Tordera RM (2010) Regulation of markers of synaptic function in mouse models of depression: chronic mild stress and decreased expression of VGLUT1. J Neurochem 114:1302-1314.
16. Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B (2009) Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 33:70-75.
17. Fumagalli F, Molteni R, Racagni G, Riva MA (2007) Stress during development: impact on neuroplasticity and relevance to psychopathology. Prog Neurobiol 81:197-217.
18. Fumagalli F, Frasca A, Racagni G, Riva MA (2008) Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs. Mol Pharmacol 73:1484-1490.
19. Fumagalli F, Calabrese F, Luoni A, Bolis F, Racagni G, Riva MA (2012) Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. Int J Neuropsychopharmacol 15:235-246.
20. Gass P, Riva MA (2007) CREB, neurogenesis and depression. BioEssays 29:957-961.
21. Hardingham GE, Bading H (2010) Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 11:682-696.
22. Heise C, Gardoni F, Culotta L, di Luca M, Verpelli C, Sala C (2014) Elongation factor-2 phosphorylation in dendrites and the regulation of dendritic mRNA translation in neurons. Front Cell Neurosci 8:35.
23. Hertz L, Zielke HR (2004) Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends Neurosci 27:735-743.
24. Hill MN, Hellemans KG, Verma P, Gorzalka BB, Weinberg J (2012) Neurobiology of chronic mild stress: parallels to major depression. Neurosci Biobehav Rev 36:2085-2117.
25. Hoeffer CA, Klann E (2010) mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 33:67-75.
26. Horisawa T, Nishikawa H, Toma S, Ikeda A, Horiguchi M, Ono M, Ishiyama T, Taiji M (2013) The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone. Behav Brain Res 244:66-69.
27. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M (2010) Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 334:171-181.
28. Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y (2007) Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 572:160-170.
29. Jernigan CS, Goswami DB, Austin MC, Iyo AH, Chandran A, Stockmeier CA, Karolewicz B (2011) The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 35:1774-1779.
30. Kang HJ, Voleti B, Hajszan T, Rajkowska G, Stockmeier CA, Licznerski P, Lepack A, Majik MS, Jeong LS, Banasr M, Son H, Duman RS (2012) Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med 18:1413-1417.
31. Karolewicz B, Szebeni K, Gilmore T, Maciag D, Stockmeier CA, Ordway GA (2009) Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. Int J Neuropsychopharmacol 12:143-153.
32. Kavalali ET, Monteggia LM (2012) Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry 169:1150-1156.
33. Kozisek ME, Middlemas D, Bylund DB (2008) Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol Ther 117:30-51.
34. Krishnan V, Nestler EJ (2010) Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 167:1305-1320.
35. Lau AG, Irier HA, Gu J, Tian D, Ku L, Liu G, Xia M, Fritsch B, Zheng JQ, Dingledine R, Xu B, Lu B, Feng Y (2010) Distinct 3'UTRs differentially regulate activity-dependent translation of brainderived neurotrophic factor (BDNF). Proc Natl Acad Sci U S A 107:15945-15950.
36. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959-964.
37. Liu Q, Li B, Zhu HY, Wang YQ, Yu J, Wu GC (2009) Clomipramine treatment reversed the glial pathology in a chronic unpredictable stress-induced rat model of depression. Eur Neuropsychopharmacol 19:796-805.
38. Luo J, Zhang L, Ning N, Jiang H, Yu SY (2013) Neotrofin reverses the effects of chronic unpredictable mild stress on behavior via regulating BDNF, PSD-95 and synaptophysin expression in rat. Behav Brain Res 253:48-53.
39. Luoni A, Hulsken S, Cazzaniga G, Racagni G, Homberg JR, Riva MA (2013) Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats. Int J Neuropsychopharmacol 16:1319-1330.
40. Luoni A, Berry A, Calabrese F, Capoccia S, Bellisario V, Gass P, Cirulli F, Riva MA (2014) Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescence. Eur Neuropsychopharmacol 24:986-995.
41. McEwen BS (2007) Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 87:873-904.
42. Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A (2011) Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placeboand olanzapine-controlled study. Am J Psychiatry 168:957-967.
43. Monteggia LM, Gideons E, Kavalali ET (2013) The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry 73:1199-1203.
44. Pariante CM, Lightman SL (2008) The HPA axis in major depression: classical theories and new developments. Trends Neurosci 31:464-468.
45. Paxinos G, Watson C (1996) The rat brain in stereotaxis coordinates. New York: Academic Press.
46. Pochwat B, Szewczyk B, Sowa-Kucma M, Siwek A, Doboszewska U, Piekoszewski W, Gruca P, Papp M, Nowak G (2014) Antidepressant- like activity of magnesium in the chronic mild stress model in rats: alterations in the NMDA receptor subunits. Int J Neuropsychopharmacol 17:393-405.
47. Radley JJ, Rocher AB, Miller M, Janssen WG, Liston C, Hof PR, McEwen BS, Morrison JH (2006) Repeated stress induces dendritic spine loss in the rat medial prefrontal cortex. Cereb Cortex 16:313-320.
48. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA (1999) Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45:1085-1098.
49. Riva MA, Donati E, Tascedda F, Zolli M, Racagni G (1994) Shortand long-term induction of basic fibroblast growth factor gene expression in rat central nervous system following kainate injection. Neuroscience 59:55-65.
50. Sanacora G, Treccani G, Popoli M (2012) Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 62:63-77.
51. Taliaz D, Loya A, Gersner R, Haramati S, Chen A, Zangen A (2011) Resilience to chronic stress is mediated by hippocampal brain-derived neurotrophic factor. J Neurosci 31:4475-4483.
52. Tarazi FI, Riva MA (2013) The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia. Expert Opin Drug Discov 8:1297-1307.
53. Vollmayr B, Bachteler D, Vengeliene V, Gass P, Spanagel R, Henn F (2004) Rats with congenital learned helplessness respond less to sucrose but show no deficits in activity or learning. Behav Brain Research 150:217-221.
54. Willner P (2005) Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52:90-110.
55. Xu W (2011) PSD-95-like membrane associated guanylate kinases (PSD-MAGUKs) and synaptic plasticity. Curr Opin Neurobiol 21:306-312.
56. Ye Y, Wang G, Wang H, Wang X (2011) Brain-derived neurotrophic factor (BDNF) infusion restored astrocytic plasticity in the hippocampus of a rat model of depression. Neurosci Lett 503:15-19.